Spruce Biosciences, Inc. (SPRB) Current Ratio
- Current ratio · latest quarter: Value 9.23×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.23× | Current assets / current liabilities. $101.15M ÷ $10.96M ≈ 9.23× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 101.15M USD | Assets, Current |
| Current obligations | 10.96M USD | Liabilities, Current |
| Cash and equivalents | 96.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.21M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 2.50M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $101.15M | $10.96M | $96.30M | (m) | (m) | (m) | $1.21M | $2.50M | 9.23× |
| 2026-03-31 | $55.03M | $11.78M | $54.08M | (m) | (m) | (m) | $2.68M | $1.00M | 4.67× |
| 2025-12-31 | $52.11M | $10.09M | $48.91M | (m) | (m) | (m) | $943.00K | $0.00 | 5.17× |
| 2025-09-30 | $14.52M | $9.43M | $10.67M | (m) | (m) | (m) | $1.39M | $539.00K | 1.54× |
| 2025-06-30 | $20.95M | $8.06M | $16.39M | (m) | (m) | (m) | $807.00K | $943.00K | 2.60× |
| 2025-03-31 | $30.58M | $15.67M | $25.61M | (m) | (m) | (m) | $1.88M | $1.34M | 1.95× |
| 2024-12-31 | $44.21M | $15.25M | $38.75M | (m) | (m) | (m) | $1.29M | $1.62M | 2.90× |
| 2024-09-30 | $63.57M | $11.86M | $60.05M | (m) | (m) | (m) | $1.80M | $1.62M | 5.36× |
| 2024-06-30 | $73.91M | $14.29M | $69.68M | (m) | (m) | (m) | $682.00K | $1.62M | 5.17× |
| 2024-03-31 | $85.86M | $18.39M | $81.15M | (m) | (m) | (m) | $1.89M | $1.62M | 4.67× |
| 2023-12-31 | $102.18M | $24.46M | $96.34M | (m) | (m) | (m) | $3.33M | $1.62M | 4.18× |
| 2023-09-30 | $111.14M | $24.19M | $98.80M | (m) | (m) | (m) | $3.15M | $1.62M | 4.59× |
| 2023-06-30 | $124.13M | $22.73M | $97.48M | (m) | (m) | (m) | $945.00K | $1.62M | 5.46× |
| 2023-03-31 | $137.24M | $23.00M | $73.93M | (m) | $15.00M | (m) | $3.45M | $1.62M | 5.97× |
| 2022-12-31 | $83.61M | $12.45M | $24.49M | (m) | (m) | (m) | $1.43M | $1.62M | 6.72× |
| 2022-09-30 | $93.19M | $12.00M | $21.65M | (m) | (m) | (m) | $2.18M | $1.22M | 7.76× |
| 2022-06-30 | $96.51M | $10.10M | $47.21M | (m) | (m) | (m) | $1.45M | $811.00K | 9.55× |
| 2022-03-31 | $95.10M | $8.97M | $23.34M | (m) | (m) | (m) | $1.11M | $405.00K | 10.60× |
| 2021-12-31 | $91.89M | $8.87M | $42.75M | (m) | (m) | (m) | $2.82M | $0.00 | 10.36× |
| 2021-09-30 | $93.92M | $9.06M | $58.36M | (m) | (m) | (m) | $2.13M | $0.00 | 10.37× |
| 2021-06-30 | $111.37M | $6.98M | $78.28M | (m) | (m) | (m) | $1.11M | $0.00 | 15.96× |
| 2021-03-31 | $151.59M | $6.85M | $148.63M | (m) | (m) | (m) | $2.57M | $0.00 | 22.13× |
| 2020-12-31 | $160.40M | $9.76M | $157.15M | (m) | (m) | (m) | $3.63M | $2.55M | 16.43× |
| 2020-09-30 | $73.60M | $10.09M | $72.16M | (m) | (m) | (m) | $4.00M | $1.91M | 7.30× |
| 2019-12-31 | $4.65M | $4.30M | $3.92M | (m) | (m) | (m) | $1.88M | $1.25M | 1.08× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |